One recent German study found that these secondary-type mutations do not impact the favorable outcome of NPM1-mutated AML (no HSCT) [94,95], whereas another synchronous American study showed that AML patients with co-mutations in MRGs and NPM1 harbor a survival similar rate to ELN 2022 intermediate risk when treated with intensive chemotherapy without VEN and that, thus, fit patients should undergo HSCT [96]. The gene discussed is NPM1; the disease is acute myeloid leukemia.